Bioplastics production capacity to quadruple by 2028
New figures published by the industry association European Bioplastics suggest a sharp increase in the production of sustainable plastics in the next two years and calls for policy support.
AZmed closes €15m Series A financing
Paris-based AI-based medical imanging specialist AZmed SA has secured a €15min Series A financing led by Maison Worms, Techstars, and Tempact Ventures.
Bayer's As^k Bio unit starts Phase II heart failure gene therapie
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
Bayer SE subsidiary Asklepios BioPharmaceutical Inc. (AskBio) has started Phase II testing of AB-1002 (NAN-101) in patients with congestive heart failure.
German companies to revolutionise lab plastics market
German Green Elephant Biotech has launched the world's first plant-based 96-well microtitre plate on the market.
AMPLY Discovery Ltd bags £1.4m funding to tackle complex diseases
Belfast-based techbio company<b> </b>AMPLY Discovery Ltd announced today will make use of a £1.4m in grant funding to advance its AI-based drug discovery platform.
Cambridge university spin-out HutanBio Ltd bags £2.25m seed financing
British-Malasian marine algae biofuel start-up HutanBio has secured an £2.25m seed investment to produce carbon negative biodiesel in brackish water.<br /><br /><br />
EU parliament votes in favour of New Genome Techniques
The European Parliament adopted its position for negotiations with Member States on the Commission's proposal on new genomic techniques (NGTs) in favour for using CRISPR/Cas as a new but now […]
EU parliament backs deregulation of New Genome Techniques
After two "Yes"-votes in the European Parliament’s AGRI and ENVI committees, MEPs confirmed the European Commissions draft Regulation on New Genomic Technologies in plant breeding.<br /> <br /><br /> <br /><br […]
Jazz Pharmaceiticals licences KRAS blocker from Redx Pharma
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.<br /><br />